Patents by Inventor Lawrence Black

Lawrence Black has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160137668
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: January 18, 2016
    Publication date: May 19, 2016
    Inventors: Hervé GENESTE, Michael OCHSE, Karla DRESCHER, Sean TURNER, Berthold BEHL, Loic LAPLANCHE, Jürgen DINGES, Clarissa JAKOB, Lawrence BLACK
  • Publication number: 20160058894
    Abstract: Compounds of formula (I) are disclosed Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as PDE10A positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compound of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Application
    Filed: September 17, 2015
    Publication date: March 3, 2016
    Inventors: Lawrence A. Black, Berthold Behl, Jill Wetter
  • Patent number: 9273068
    Abstract: The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X1, X2, X3, R1 and R2 are defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: March 1, 2016
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Sean Turner, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Lawrence Black
  • Patent number: 9138494
    Abstract: Compounds of formula (I) are disclosed Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as PDE10A positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compound of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 22, 2015
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Lawrence A. Black, Berthold Behl, Jill Wetter
  • Patent number: 9108948
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R3a, R3b, R4, and R5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: August 18, 2015
    Assignee: AbbVie Inc.
    Inventors: Huaqing Liu, Lawrence A. Black, Youssef L. Bennani, Marlon D. Cowart, Zhenping Tian, Paul J. Brackemeyer
  • Patent number: 8829041
    Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: September 9, 2014
    Assignee: AbbVie Inc.
    Inventors: Huaqing Liu, Lawrence A. Black, Youssef L. Bennani, Marlon D. Cowart
  • Patent number: 8796297
    Abstract: Compounds of the formula wherein R1 and R2 are as disclosed herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor full or partial agonists. Also disclosed are pharmaceutical compositions, methods for using such compounds and compositions, and processes for preparing the compounds.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: August 5, 2014
    Assignee: AbbVie Inc.
    Inventors: Lawrence A. Black, Gregory A. Gfesser, Marlon D. Cowart
  • Publication number: 20140148461
    Abstract: The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: November 22, 2013
    Publication date: May 29, 2014
    Inventors: Hervé GENESTE, Sean Colm TURNER, Michael OCHSE, Karla DRESCHER, Lawrence A. BLACK, Katja JANTOS
  • Patent number: 8735411
    Abstract: Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: May 27, 2014
    Assignee: AbbVie Inc.
    Inventors: Robert J. Altenbach, Huaqing Liu, Irene Drizin, Marlon D. Cowart, Neil Wishart, David J. Babinski, Robert J. Gregg, Timothy A. Esbenshade, Gin C. Hsieh, Jorge D. Brioni, Marie P. Honore, Lawrence A. Black, Chen Zhao, Brian D. Wakefield, Kathryn J. Hancock
  • Publication number: 20140120036
    Abstract: Compounds of formula (I) are disclosed Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by 5-HT6 receptor ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as 5-HT6 positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Application
    Filed: December 21, 2012
    Publication date: May 1, 2014
    Inventor: Lawrence A. Black
  • Patent number: 8580968
    Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: November 12, 2013
    Assignee: AbbVie Inc.
    Inventors: Lawrence A. Black, Marlon D. Cowart, Gregory A. Gfesser, Brian D. Wakefield, Robert J. Altenbach, Huaqing Liu, Chen Zhao, Gin C. Hsieh
  • Patent number: 8436005
    Abstract: Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: May 7, 2013
    Assignee: Abbott Laboratories
    Inventors: Huaqing Liu, Irene Drizin, John R. Koenig, Marlon D. Cowart, Chen Zhao, Brian D. Wakefield, Lawrence A. Black, Robert J. Altenbach
  • Patent number: 8399468
    Abstract: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: March 19, 2013
    Assignee: Abbott Laboratories
    Inventors: Marlon D. Cowart, Chen Zhao, Minghua Sun, Lawrence A. Black, Guo Zhu Zheng, Robert J. Gregg, Geoff G. Z. Zhang, Ahmad Y. Sheikh, Xiaochun Lou, Rodger F. Henry, David M. Barnes, Lawrence Kolaczkowski, Anthony R. Haight, Sou-Jen Chang, Steven J. Wittenberger, Michael G. Fickes
  • Patent number: 8278313
    Abstract: Macrocyclic Spiro pyrimidine compounds of formula (I): compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: October 2, 2012
    Assignee: Abbott Laboratories
    Inventors: Huaqing Liu, John R. Koenig, Marlon D. Cowart, Lawrence A. Black
  • Patent number: 8273767
    Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: September 25, 2012
    Assignee: Abbott Laboratories
    Inventors: Robert J. Altenbach, Lawrence A. Black, Sou-Jen Chang, Marlon D. Cowart, Ramin Faghih, Gregory A. Gfesser, Yi-Yin Ku, Huaqing Liu, Kirill A. Lukin, Diana L. Nersesian, Yu-ming Pu, Padam N. Sharma, Youssef L. Bennani, Michael P. Curtis
  • Patent number: 8268846
    Abstract: Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: September 18, 2012
    Assignee: Abbott Laboratories
    Inventors: Brian D. Wakefield, Robert J. Altenbach, Lawrence A. Black, Marlon D. Cowart, Irene Drizin, Huaqing Liu
  • Publication number: 20120164070
    Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.
    Type: Application
    Filed: March 1, 2012
    Publication date: June 28, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Lawrence A. Black, Marlon D. Cowart, Gregory A. Gfesser, Brian D. Wakefield, Robert J. Altenbach, Huaqing Liu, Chen Zhao, Gin C. Hsieh
  • Patent number: 8153813
    Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: April 10, 2012
    Assignee: Abbott Laboratories
    Inventors: Lawrence A. Black, Marlon D. Cowart, Gregory A. Gfesser, Brian D. Wakefield, Robert J. Altenbach, Huaqing Liu, Chen Zhao, Gin C. Hsieh
  • Patent number: 8026240
    Abstract: The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of CNS-active compounds, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of treating conditions and disorders using such compounds and compositions. Octahydro-pyrrolo[3,4-b]pyrrole N-oxides of formula (I) are prodrugs of histamine-3 antagonists, and are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole N-oxide compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: September 27, 2011
    Assignee: Abbott Laboratories
    Inventors: Marlon D. Cowart, Kennan C. Marsh, Huaqing Liu, Jae Y. Lee, Maria G. Beconi, Jill M. Wetter, Lawrence A. Black, Thomas C. Custer
  • Patent number: 7985745
    Abstract: This invention discloses a method of treating pain by administering histamine H4 receptor ligands and compositions comprising the same.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: July 26, 2011
    Assignee: Abbott Laboratories
    Inventors: Marlon D. Cowart, Robert J. Altenbach, Huaqing Liu, Irene Drizin, Neil Wishart, David J. Babinski, Robert J. Gregg, Arthur A. Hancock, Kathryn J. Hancock, legal representative, Timothy A. Esbenshade, Gin C. Hsieh, Jorge D. Brioni, Marie P. Honore, Lawrence A. Black, Chen Zhao, Brian D. Wakefield